Company Profile
Brainstorm Cell Therapeutics Inc. Stock Price, News & Analysis
- Ticker:
- BCLI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel
Stock performance
0.80 USD (+3.10%)
Close
Last updated: August 6, 2026
—
Market cap
Why the stock is moving
As of Aug 6, 2026, BCLI closed up 3.10% at $0.8000. No new same-company headline was identified in the current news window.
Company overview
Business overview
BrainStorm Cell Therapeutics is a cell-therapy company focused on neurological disease, especially ALS. Its platform has long been tied to a high-risk, high-conviction neurodegeneration story.
Geographic Base and Sector Classification
Headquartered in Israel and listed on NASDAQ, BrainStorm sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical validation, regulatory steps, and the ability to turn cell-therapy science into value.
Position Within the Biotechnology Landscape
BrainStorm is a highly catalyst-sensitive neuroscience name with strong dependence on clinical outcomes.
Future catalysts
The main thing to watch at Brainstorm Cell Therapeutics is MSC-NTF and ALSFRS-R. The update that sharpened the story was "The team at BrainStorm is focused on completing the final steps required to initiate our planned Phase 3 ENDURANCE study of NurOwn in ALS," said Chaim Lebovits, President and CEO. That is the part of the story investors will probably keep circling back to. The partnership angle also matters here, especially around Successful completion of Part A of the study is anticipated to generate the clinical data required to support a new Biologics License Application (BLA) submission for NurOwn.
Recent news
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
Source: Brainstorm Cell Therapeutics Inc.
- 02
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
Source: Brainstorm Cell Therapeutics Inc.
- 03
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
Source: Brainstorm Cell Therapeutics Inc.
- 04
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
Source: Brainstorm Cell Therapeutics Inc.
- 05
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Source: Brainstorm Cell Therapeutics Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Brainstorm Cell Therapeutics Inc. (BCLI)?
Brainstorm Cell Therapeutics Inc. (BCLI) most recently closed at 0.80 USD, a +3.10% move versus the previous session.
What does Brainstorm Cell Therapeutics Inc. do?
BrainStorm Cell Therapeutics is a cell-therapy company focused on neurological disease, especially ALS. Its platform has long been tied to a high-risk, high-conviction neurodegeneration story.
On which exchange is BCLI stock listed?
Brainstorm Cell Therapeutics Inc. (BCLI) is associated with NASDAQ, Israel, Biopharma.
What is MSC-NTF?
The main thing to watch at Brainstorm Cell Therapeutics is MSC-NTF and ALSFRS-R.
Which conditions is Brainstorm Cell Therapeutics Inc. targeting with MSC-NTF?
The main thing to watch at Brainstorm Cell Therapeutics is MSC-NTF and ALSFRS-R.
How does Brainstorm Cell Therapeutics Inc. describe recent progress with MSC-NTF?
The main thing to watch at Brainstorm Cell Therapeutics is MSC-NTF and ALSFRS-R.
What is ALSFRS-R?
The main thing to watch at Brainstorm Cell Therapeutics is MSC-NTF and ALSFRS-R.
What should investors watch for with ALSFRS-R?
The main thing to watch at Brainstorm Cell Therapeutics is MSC-NTF and ALSFRS-R.